Please use this button to safely reload the folder counts on your home page
Updated March 1, 2024. Red font indicates the latest edits and changes.
We request that all manuscripts be submitted online at https://www.jaccsubmit-cardiooncology.org. Manuscript submissions should conform to the guidelines set forth in the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication" which are available at http://www.icmje.org. For English language editing services, Elsevier can direct authors upon request to a service that can assist with this prior to submission. Please visit https://webshop.elsevier.com/language-editing-services/language-editing.
Creative Commons Attribution-Noncommercial-NoDerivs (CC BY-NC-ND). For non-commercial purposes, this license allows others to distribute and copy the article and include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.
If you need to comply with your funding body policy, you can apply for a CC-BY license after your manuscript is accepted for publication.
To provide open access, this journal has an open access fee (also known as an article publishing charge, aka APC) which needs to be paid by the authors, or, for example, on their behalf by their research funding organization or institution. The open access fee for full Original Investigations is $3,866, and $1,600 for Research Letters with a 10% discount for American College of Cardiology members. We also offer a discount of 50% if the first, corresponding, or senior author is from a developing country. (Note: Discounts exclude taxes and are not cumulative.) Other manuscript submissions will not be subject to an APC charge. Learn more about Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing
After acceptance, open access papers will be published under a noncommercial license. For authors requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.
Each author must have contributed significantly to the submitted work. The contribution of each author should be delineated in the cover letter. If authorship is attributed to a group (either solely or in addition to 1 or more individual authors), all members of the group must meet the full criteria and requirements for authorship. To save space, if group members have been previously published, the article should be referenced rather than reprinting the list of names. The Editors consider authorship to include all of the following:
Participation solely in the collection of data does not justify authorship but may be appropriately acknowledged in the Acknowledgment section. Manuscripts must be submitted with a cover letter stating:
Please note that copyright is now handled by the publisher and no copyright form will be sent to you until the manuscript has been sent to the publisher. Only authors appearing on the final title page will be sent a relationship with industry form. YOU CANNOT ADD AUTHORS AFTER ACCEPTANCE OR ON PROOFS.JACC: CardioOncology publishes the following manuscript types: Original Investigations, State-of-the-Art Reviews, Primers in Cardio-Oncology, Research Letters, Clinical Case Challenges, Viewpoints, and Letters to the Editor. Regardless of manuscript type, each publication should answer the question: "How does this work potentially impact the clinical care of cancer patients?"
Elsevier will maintain copyright records for the College. Sharing of data from manuscripts that are under review or accepted but not yet published is expressly forbidden, unless permission is received from the JACC Journals Editorial Office. We ask that authors disclose this information during the submission process.
JACC Journals does not consider the posting of manuscripts to a preprint server a prior publication, if they have not undergone peer review and provided that the following conditions are met: 1) when submitting a manuscript to a JACC journal, authors must acknowledge preprint server deposition and provide all associated accession numbers or DOIs; 2) versions of a manuscript that have been altered as a result of our peer review process may not be deposited; 3) the preprint version cannot have been indexed in MEDLINE or PubMed; and 4) upon publication in a JACC journal, authors are responsible for updating the archived preprint with a DOI and link to the published version of the article. Should the paper be accepted and published in a JACC journal, that JACC journal DOI should be considered to be the one representing this published work in all credits, citation, and attribution.
Please be sure you have obtained or will obtain permission for previously published tables, figures, or any material for which you cannot grant copyright.
Click here for a template to use in formatting your submission:https://www.jaccsubmit-cardiooncology.org/html/SFPTemplate.docx
The "How To" Series is a type of short-form primer, typically invited, designed to offer very practical guidance regarding the diagnosis and management of clinical scenarios based upon available evidence and expert consensus in the absence of detailed evidence. Example clinical cases are necessary, followed by a discussion of the relevant diagnostic, therapeutic, and management issues. Details regarding the management are meant to be succinct, clinically relevant and actionable. Seminal references informing the decision process should be cited. An example of this manuscript type can be found here: https://www.jacc.org/doi/10.1016/j.jaccao.2020.07.010).
Authors should detail in their cover letters how their submission differs from existing publications on this topic. Click here for a template to use in formatting your submission: https://www.jaccsubmit-cardiooncology.org/html/LFPTemplate.docx
Please be sure you have obtained or will obtain permission for previously published tables, figures, or any material for which you cannot grant copyright.
Articles are discrete, highly significant, innovative or novel findings reported in a shorter format of 1,000 words or less in length. Click here for a template to use in formatting your submission: https://www.jaccsubmit-cardiooncology.org/html/RLTemplate.docx
Although usually invited, succinct opinion pieces relevant to a specific aspect of cardio-oncology will also be considered for JACC: CardioOncology.They should not exceed 2,000 words and should have an important and direct clinical implication. It is recommended that a query first be sent to jaccco@acc.org before submitting this manuscript. Click here for a template to use in formatting your submission: https://www.jaccsubmit-cardiooncology.org/html/VPTemplate.docx
These pieces will succinctly describe a clinical case in cardio-oncology that highlights a specific challenge in medical care. The step-by-step diagnostic and management approaches will be detailed. A clinical, evidence-based perspective on the current available literature to support the approach to care is mandatory and should be included. Click here for a template to use in formatting your submission: https://www.jaccsubmit-cardiooncology.org/html/CCCTemplate.docx
JACC: Cardio:Oncology will publish a limited number of letters that focus on a specific manuscript that has appeared in the journal. Letters must be submitted within 3 months of the issue date of the article. JACC: CardioOncology does not consider letters to the editor on review articles, editorials, or any correspondence, including research letters. Letters should be submitted online at www.jaccsubmit-cardiooncology.org. Click here for a template to use in formatting your submission: https://www.jaccsubmit-cardiooncology.org/html/LERLETemplate.docx
The entire manuscript (including tables) should be uploaded as a Microsoft Word document, with 1-inch margins and 12-point Times New Roman font. The title and abstract pages, including keywords and abbreviations, should be single-spaced. All text from the introduction to the end (including tables) should be double-spaced. Page numbering should start with the title page.
An unstructured 150-word abstract should be provided for review articles and long-form primers.
These are for original investigations only.
The authors should delineate clinical implications/competency in medical knowledge or patient care and translational outlook recommendations for their manuscripts. These should be listed in the manuscript after the Text and before the References. Please review the examples provided below.
The implications describe the consequences of the study for current practice. The translational outlook identifies the potential barriers to clinical translation, emphasizing directions for additional research.
Competency in Medical Knowledge or Competency in Patient Care. Competency-based learning in cardiovascular medicine addresses the 6 domains promulgated by the Accreditation Council on Graduate Medical Education (ACGME) and endorsed by the American Board of Internal Medicine (Medical Knowledge, Patient Care and Procedural Skills, Interpersonal and Communication Skills, Systems-Based Practice, Practice-Based Learning, and Professionalism) (htttp://www.acgme.org/acgmeweb). The ACCF has adopted this format for its competency and training statements, career milestones, lifelong learning, and educational programs. The ACCF also has developed tools to assist physicians in assessing, enhancing, and documenting these competencies http://www.acc.org/education-and-meetings/products-and-resources/competencies. Authors are asked to consider the clinical implications of their report and identify applications in one or more of these competency domains that could be used by clinician readers to enhance their competency as professional caregivers and the potential impact on the clinical care of cancer patients. This applies not only to physicians in training, but to the sustained commitment to education and continuous improvement across the span of their professional careers.
Translational Outlook.Translating biomedical research from the laboratory bench, clinical trials or global observations to the care of individual patients can expedite discovery of new diagnostic tools and treatments through multidisciplinary collaboration. Effective translational medicine facilitates implementation of evolving strategies for prevention and treatment of disease in the community. The Institute of Medicine identified two areas needing improvement: testing basic research findings in properly designed clinical trials and, once the safety and efficacy of an intervention has been confirmed, more efficiently promulgating its adoption into standard practice (Sung NS, Crowley WF, Genel M. The meaning of translational research and why it matters. JAMA 2008;299:3140-3148). The National Institutes of Health (NIH) has recognized the importance of translational biomedical research, emphasizing multifunctional collaborations between researchers and clinicians to leverage new technology and accelerate the delivery of new therapies to patients (htttp://www.ncats.nih.gov/about/). Authors are asked to place their work in the context of the scientific continuum, by identifying impediments and challenges requiring further investigation and anticipating next steps and directions for future research. Authors should briefly reflect on how their work potentially impacts the clinical care of cancer patients.
These are for State-of-the-Art Reviews and Primers Only.
Please provide a list of 3-4 brief (of no more than 15 words each) bullet points that highlight the main messages of the review. The first bullet should provide the translational/clinical context or background that establishes the relevance or need for this review. The second bullet should speak to the main message and focus of the review, including any recommendations made by the authors. The final bullet should summarize where the field needs to move forward from this point.
Example
ALL ORIGINAL INVESTIGATIONS, STATE OF THE ART REVIEWS, AND LONG-FORM PRIMERS SHOULD INCLUDE A CENTRAL ILLUSTRATION.
Central Illustrations serve to succinctly summarize the entire manuscript or at least a major section of the manuscript. Upon acceptance, our in-house medical illustrators will assist in creating the final versions of these figures in consultation with the authors and the editors. The purpose of these illustrations is to provide a snapshot of your paper in a single visual, conceptual manner.
This illustration must be accompanied by a legend consisting of a title and caption of no more than 50-100 words in total. The title should be no more than 10 words. The Central Illustration legend should be listed last in your list of figure legends. For best practices on creating Central Illustrations, please see The Art and Challenge of Crafting a Central Illustration or Visual Abstract at https://www.jacc.org/doi/full/10.1016/j.jacc.2019.10.035
Graphics software, such as Photoshop and Illustrator, should be used to create the art, but not presentation software such as PowerPoint, CorelDraw, or Harvard Graphics. Line art (black and white or color) and combinations of gray scale images and line art should be at least 1200 DPI. Lettering should be of sufficient size to be legible after reduction for publication. The optimal size is 12 points. Symbols should be of a similar size. Figures should be no smaller than 13 cm x 18 cm (500 x 700). Decimals, lines, and other details must be strong enough for reproduction. Use only black and white-not gray-in charts and graphs. Place crop marks on photomicrographs to show only the essential field. Designate special features with arrows. All symbols, arrows, and lettering on half-tone illustrations must contrast with the background.
There is no fee for the publication of color figures. Our editors encourage authors to submit figures in color, as we feel it improves the clarity and visual impact of the images.
Please upload all supplemental materials, with the exception of videos and large data sets (see below), as one separately uploaded Word document that is labeled “Supplemental Appendix.” The pages of the Supplemental Appendix should be numbered consecutively. The first page of the Supplemental Appendix should list the title of the manuscript and the contents of the supplement, including the title and page number of each element included in the document.
The Supplemental Appendix document may include the following elements:
All references that are cited within supplemental material should be placed in a separate reference section that is at the end of the supplemental material. The references should be formatted just as in the main manuscript and numbered and cited consecutively in the Supplemental Appendix.
All supplemental material will undergo editorial and peer review at the same time as the main manuscript is being evaluated. Once the manuscript is accepted for final publication, the content of the supplemental material cannot be changed.
If a figure/table is reprinted or adapted from a previously published work, permission must be obtained from that publisher (or copyright holder, if not the publisher) and sent to the editorial office. Please also see Figures/Central Illustrations. If a manuscript includes excerpts of published text longer than 50 words, permission from the copyright holder to republish the text is required.
Manuscript submissions should conform to the guidelines set forth in the "Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals," available online at http://www.icmje.org/recommendations.
Studies should be in compliance with human studies committees and animal welfare regulations of the authors' institutions and the U.S. Food and Drug Administration guidelines. Human studies must be performed with the subjects' written informed consent. Authors must provide the details of this procedure and indicate that the institutional committee on human research has approved the study protocol. If radiation is used in a research procedure, the radiation exposure must be specified in the Methods.
Clinical trials should be registered. Studies on patients or volunteers require ethics committee approval and informed consent which should be documented in your paper. Patients have a right to privacy. Therefore, identifying information, including patients' images, names, initials, or hospital numbers, should not be included in videos, recordings, written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and you have obtained written informed consent for publication in print and electronic form from the patient (or parent, guardian or next of kin where applicable).
If such consent is made subject to any conditions, the editorial office must be made aware of all such conditions. Written consents must be provided to the editorial office on request. Even where consent has been given, identifying details should be omitted if they are not essential.
If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note. If such consent has not been obtained, personal details of patients included in any part of the paper and in any supplementary materials (including all illustrations and videos) must be removed before submission.
Animal investigation must conform to the "Position of the American Heart Association on Research Animal Use," adopted by the AHA on November 11, 1984. If equivalent guidelines are used, they should be indicated. The AHA position includes: 1) animal care and use by qualified individuals, supervised by veterinarians, and all facilities and transportation must comply with current legal requirements and guidelines; 2) research involving animals should be done only when alternative methods to yield needed information are not possible; 3) anesthesia must be used in all surgical interventions, all unnecessary suffering should be avoided and research must be terminated if unnecessary pain or fear results; and 4) animal facilities must meet the standards of the American Association for Accreditation of Laboratory Animal Care (AAALAC).
Ethical Approval:. Ethical Approval: Please denote that your study received the proper ethical oversight in both your cover letter and the first paragraph of your Methods section. For manuscripts reporting data on human subjects, note institutional review board/ethics committee approval (or formal review and exemption), including the specific name of the board or committee. For studies involving animal experiments, note that the study complied with all institutional and national requirements for the care and use of laboratory animals and, if applicable, received animal care and use committee approval. State the animal-handling protocol in your Methods.
This journal encourages and enables you to share data that supports your research publication where appropriate and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page: https://www.elsevier.com/authors/author-services/research-data
Data statement: To foster transparency, we encourage you to state the availability of your data in your submission. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. For more information, visit the Data Statement page: https://www.elsevier.com/authors/author-services/research-data/data-profile
All forms are now signed and submitted electronically. Once a manuscript is accepted, the authors will be sent links to complete the electronic Relationship with Industry forms. Elsevier now handles copyright for the journal. Only the corresponding author may electronically sign the copyright form; however, all authors are required to electronically sign a relationship with industry form. Once completed, a PDF version of the form is e-mailed to the author. Authors can access and confirm receipt of forms by logging into their account at https://www.jaccsubmit-cardiooncology.org. Each author will be alerted if his or her form has not been completed by the deadline.
The JACC Journals program prefers the term Relationships with Industry and Other Entities as opposed to the term Conflict of Interest, because, by definition, it does NOT necessarily imply a conflict. When all relationships are disclosed with the appropriate detail regarding category and amount, and managed appropriately for building consensus and voting, the JACC Journals program believes that potential bias can be avoided and the final published document is strengthened since the necessary expertise is accessible.
Please disclose in the cover letter and in the acknowledgement section (the latter of which is published, if the paper is accepted) if any artificial intelligence (AI) programs (e.g., ChatGPT, or other similar software) contributed to the compilation of the submitted manuscript as well as the nature of the contribution that the tool provided. This could include design, performance, analysis, writing, and reporting of the work.
Guest Editors: Editors are not involved in decisions about papers which they have written themselves or have been written by family members or institutional colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups.
JACC Journals have adopted integrity guidelines to help authors uphold the ethics, values, and principles of the publication process at the highest standards. The guidelines below include best practices and are consistent with those implemented by other journals and scientific publishers.
The Office of Research Integrity (ORI) defines plagiarism as "theft or misappropriation of intellectual property and the substantial unattributed textual copying of another's work." Manuscripts where unacknowledged copying of others' ideas, language and/or results will not be published in JACC Journals and, depending on level of egregiousness, will be reported to ORI and/or other agencies. Therefore, authors should ensure that appropriate attribution and citation is provided when discussing, paraphrasing, or summarizing the work of others. Included is the use of one's own text from previous publications (exclusive of materials and methods), where appropriate attribution and citation is necessary. Reuse of one's own or others' previously published data, whether it be publishing the same paper in multiple journals or adding incremental new data to a previous publication without providing appropriate references, will be considered a duplicate publication.
Should JACC Journals discover acts of plagiarism pre-publication, the publication process will be halted until the matter is resolved. Should JACC Journals discover acts of plagiarism post-publication, an investigation to determine the extent and context of the plagiarism will be conducted. JACC Journals reserve the right to correct or retract any publication based on the findings of said investigations.
Authors must discuss, properly cite, and provide appropriate permissions for any unpublished work included in submitted manuscripts. Any data, intellectual contribution, and/or technical development, including unpublished data from databases, must be acknowledged and appropriately cited. Authors must include written assurance that they are complying with the data-licensing agreements of the original source documents when using licensed data. If an author is reusing or modifying previously published or copyrighted figures, documented permission from the previous publisher or copyright holder is required.
Material submitted to a JACC Journal must be original. Submitted material cannot have been previously published and cannot be simultaneously submitted elsewhere (exclusive of meeting abstracts). Related manuscripts under consideration or in press elsewhere must be declared by authors submitting to a JACC Journal at the time of submission in the cover letter. If related material is submitted elsewhere after submission to a JACC Journal, authors must notify the JACC Journal immediately.
All data and figures published in JACC Journals must accurately represent the original data and findings. Misrepresentation of data acquisition and/or post-acquisition processing is not acceptable.
While JACC Journals understand minor data processing may be unavoidable, submitted digital images must be as close to original as possible. Processing/image adjustment (e.g., contrast or brightness) must be applied equally across the entire image and any relevant controls. Any image processing/adjustment should not make data disappear or mask additional bands. Authors should explain any image alterations in the figure legend and identify image acquisition tools and processing software in the methods. Integral settings and processing manipulations used to process the presented data should also be described.
JACC Journals reserve the right to request all unprocessed data files included in a submitted manuscript. Manuscript evaluation may be halted or discontinued if the files are not available upon request.
Authors should take care to adhere to the following specific concerns:
Quantitative comparisons between samples on different gels/blots should be avoided, and only performed when normalizing controls are available for both gels. Protein loading controls must be run on the same blot. If unavoidable, the figure legend must indicate that the samples are derived from the same or parallel experiments and that the gels/blots are processed in parallel.
Removal of irrelevant or blank lanes from a gel is permissible; however, such alterations must be noted in the figure legend and boundaries between the nonadjacent or rearranged lanes must be clearly marked in the figure.
Microscopy settings for comparable controls and samples should be the same between experiments. Any necessary nonlinear, pseudocolor, or color adjustments made to images must be stated in the figure legend. Any manipulation of threshold and expansion or contraction of signal ranges should be avoided.
Authors should not combine images obtained separately, at different times, or from different locations, into a single image, unless specifically stated in the figure legend.
Continuous data and small sample sizes should be represented with figures that show full data distribution, such as dot or scatter plots. Bar graphs should be avoided except when showing counts or proportions.
Authors should consider adding a flow chart or study design diagram when appropriate. Flow charts should provide information about excluded observations and reasons for exclusion at each phase of the study.
English language help service: For English language editing services, Elsevier can direct authors upon request to a service that can assist with this prior to submission. Please visit https://webshop.elsevier.com/language-editing-services/language-editing/ for further information.